Over the past six months, Solid Biosciences' stock (SLDB) has seen several events. Analyst coverage and ratings include Guggenheim initiating a 'Buy' (March 20, 2026), RBC Capital initiating an 'Outperform' with an $18 price target (September 16, 2026), Citi reiterating a 'Buy' (September 12, 2026), and Cantor Fitzgerald reiterating an 'Overweight' with a $26 price target, calling it a 'top pick.' The consensus among analysts is a 'Moderate Buy' or 'Strong Buy' with an average price target around $18.62 to $18.69, implying substantial upside. Clinical and regulatory milestones include positive FDA feedback from a Type C meeting for SGT-003 (February 9, 2026), European Commission granting Orphan Drug Designation for SGT-003 (April 28, 2026), and dosing the first participant in the Phase 3 IMPACT DUCHENNE trial for SGT-003 (May 2026, anticipated April 2026). The company expects initial safety data for SGT-501 in the second half of 2026 and preliminary data from the FALCON trial for SGT-212 before the end of 2026. Management also outlined an upcoming six-month catalyst window, including an FDA meeting in Q4 2026 on a potential Accelerated Approval path for its Duchenne muscular dystrophy gene therapy. Financial and corporate news includes reporting Q4 and full-year 2025 financial results and a business update on March 19, 2026, which included the completion of a $240 million private placement, extending its cash runway into the first half of 2028. On August 6, 2026, SLDB last reported earnings, with shares declining 3.7% the day after. On October 1, 2026, the company announced a grant of restricted stock units to a newly hired employee. Stock price movement shows a year-to-date rally of roughly 58% from $5.64 at the start of 2026 to $8.92 by September 16, 2026. However, the stock has recently fallen by -17.42% in the past week and by -28.54% over the past month. It declined nearly 5% as investors weighed presentation details from Citi's Biopharma Back to School Summit regarding an upcoming FDA meeting and tumbled roughly 10% in early October 2026 as biotech names broadly sold off amid a sharp rise in Treasury yields. As of October 7, 2026, SLDB was in a downward trend, declining for three consecutive days.
